112 results
Page 5 of 6
8-K
EX-99.2
7pyvj
17 Oct 19
Syros Announces Update on Selective CDK7 Inhibitor Portfolio
8:30am
8-K
ihbrl3swf
17 Oct 19
Syros Announces Update on Selective CDK7 Inhibitor Portfolio
8:30am
8-K
EX-99.1
kren77f
17 Oct 19
Syros Announces Update on Selective CDK7 Inhibitor Portfolio
8:30am
8-K
EX-99.1
11beib1 cn0lbd8bo
24 Apr 19
Regulation FD Disclosure
8:31am
424B5
1gwhtdddvavfg7
8 Apr 19
Prospectus supplement for primary offering
12:00am
8-K
EX-1.2
kbbswli 47hxn49
8 Apr 19
Entry into a Material Definitive Agreement
12:00am
8-K
EX-1.1
j0jwjvyden09kzthdue
8 Apr 19
Entry into a Material Definitive Agreement
12:00am
424B5
5r874su02ywbc
8 Apr 19
Prospectus supplement for primary offering
12:00am
424B5
ym7w3jfi 0fx43
4 Apr 19
Prospectus supplement for primary offering
4:15pm
424B5
l8qkl s7r3j
4 Apr 19
Prospectus supplement for primary offering
4:13pm
8-K
EX-10.1
rjjym88y vxc9vtepybq
11 Jan 19
Entry into a Material Definitive Agreement
5:02pm
8-K
EX-99.1
x0mvbavt 7i
7 Jan 19
Regulation FD Disclosure
6:30am
8-K
EX-99.2
3ruk1
7 Jan 19
Regulation FD Disclosure
6:30am
8-K
q8w8f2i7fhsuhmylp6
3 Dec 18
Syros Announces Promising Clinical Data from Ongoing Phase 2 Trial of SY-1425 in Genomically Defined AML and MDS Patients at ASH Annual Meeting
8:07am
8-K
EX-99.1
t1dg14y9ds0swm8ucc
3 Dec 18
Syros Announces Promising Clinical Data from Ongoing Phase 2 Trial of SY-1425 in Genomically Defined AML and MDS Patients at ASH Annual Meeting
8:07am
8-K
EX-99.2
bomtktn4nk9gymh
15 Nov 18
Regulation FD Disclosure
4:03pm